Vimarsana
Biggest News Aggregation in the World

Note Repurchases News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Note Repurchases. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Note Repurchases Today - Breaking & Trending Today

RingCentral Announces Fourth Quarter and Fiscal Year 2023 Results - Vimarsana News

RingCentral Announces Fourth Quarter and Fiscal Year 2023 Results

20.02.2024 - RingCentral, Inc. (NYSE:RNG), a leading provider of AI-driven cloud business communications, contact center, video and hybrid event solutions, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023. Fourth ...

RingCentral Announces Repurchase of Approximately $253 Million of Convertible Notes - Vimarsana News

RingCentral Announces Repurchase of Approximately $253 Million of Convertible Notes

RingCentral, Inc. , a leading provider of AI-first global enterprise cloud communications, video, webinars, hybrid events, and contact center solutions, today announced that it has entered into...

RingCentral Announces Second Quarter 2023 Results - Vimarsana News

RingCentral Announces Second Quarter 2023 Results

BELMONT, Calif.--(BUSINESS WIRE)--Aug 7, 2023--

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027 - Vimarsana News

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027

Share this article Share this article SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced the pricing of $700 million aggregate principal amount of its convertible senior notes due 2027 (the "Convertible Notes"). The Convertible Notes are being offered in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Company granted an option to the initial purchasers ...

Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027 - Vimarsana News

Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027

Share this article Share this article SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced that it intends to offer, subject to market conditions and other factors, $500 million aggregate principal amount of convertible senior notes due 2027 (the "Convertible Notes"). The Convertible Notes are to be offered and sold to "qualified institutional buyers" pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Company a...